MedTrace Logo

An Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia

NCT05422677 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4698

Last updated 2022-06-22

No results posted yet for this study

Summary

In this study, BPH patients visited the institutions during the study period and the effectiveness and safety of the treatment of Tamsulosin(Hanmi Tams® Capsule) in real-practice.

During the routine medical visit, according to the investigator's judgment, with diagnosis that the Tamsulosin prescription is appropriate, and after deciding to start treatment, patients with BPH who agreed to participate in the study were administered Tamsulosin.

As this study is a non-interventional observational study, all subjects received prescriptions according to the routine treatment procedure, and there were no visits or procedures required according to the observational study protocol.

Conditions

  • BPH
  • Benign Prostatic Hyperplasia

Interventions

DRUG

Hanmi Tams® Capsule

Hanmi Tams®, Once daily administered per the locally approved product information

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Ji-yeon Hong · Hanmi Pharmaceutical Company Limited

Eligibility

Min Age
19 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-15
Primary Completion
2021-08-24
Completion
2021-08-24

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05422677 on ClinicalTrials.gov